April 26, 2017
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) today approved the VisuMax Femtosecond Laser (Carl Zeiss Meditec) to remove a sliver of corneal tissue to reduce or eliminate myopia in certain adults aged 22 years or older, the agency announced today./"...



How Supplied


Mitosol® is an antimetabolite indicated for use as an adjunct to ab externo glaucoma surgery.


Mitosol® is intended for topical application to the surgical site of glaucoma filtration surgery. It is not intended for intraocular administration. If intraocular administration occurs, cell death leading to corneal infarction, retinal infarction, and ciliary body atrophy may result.

Method of Reconstitution: Each vial of Mitosol® contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. To reconstitute, add 1 mL of Sterile Water for Injection, then shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until the product dissolves into solution.

Method of Use: Sponges provided within the Mitosol® Kit should be fully saturated with the entire reconstituted contents in the manner prescribed in the Instructions for Use. A treatment area approximating 10mm x 6mm +/- 2mm should be treated with the Mitosol®. Apply fully saturated sponges equally to the treatment area, in a single layer, with the use of a surgical forceps. Keep the sponges on the treatment area for two (2) minutes, then remove and return to the Mitosol® Tray for defined disposal in the Chemotherapy Waste Bag provided.


Lyophilized Mitosol® stored at controlled room temperature (i.e., 20 - 25°C or 68° - 77° F) is stable for the shelf life indicated on the package. Avoid excessive heat. Protect from light.

Reconstituted with Sterile Water for Injection at a concentration of 0.2 mg/ml, mitomycin is stable for one (1) hour at room temperature.


Dosage Forms and Strengths

Mitosol® is a sterile lyophilized mixture of mitomycin and mannitol, which, when reconstituted with Sterile Water for Injection, provides a solution for application in glaucoma filtration surgery. Mitosol® is supplied in vials containing 0.2 mg of mitomycin. Each vial also contains mannitol 0.4 mg, at a 1:2 ratio of mitomycin to mannitol. Each mL of reconstituted solution contains 0.2 mg mitomycin and has a pH between 5.0 and 8.0. 4.

Mitosol® (mitomycin for solution) is available in a kit containing:

One   Vial containing 0.2 mg mitomycin
One   1 mL syringe (Sterile Water For Injection) with Connector
One   Plunger Rod
One   Vial Adapter with Spike
One   1 mL TB Syringe, Luer Lock
One   Sponge Container
Six   3 mm Absorbent Sponges
Six   6 mm Absorbent Sponges
Six   Half Moon Sponges
One   Instrument Wedge Sponge
One   Alcohol Prep Pad, Sterile
One   Chemotherapy Waste Bag

Three kits are supplied in each carton (NDC 49771-002-03).

Storage and Handling


Store kits at 20° - 25° C (68° - 77° F). Protect from light.

Handling Procedures

Procedures for Proper Handling and Disposal of anti-cancer drugs should be followed. Appropriate containment and disposal devices are included within the Mitosol® (mitomycin for solution) Kit for Ophthalmic Use.

Manufactured for: Mobius Therapeutics, LLC 4041 Forest Park Avenue St. Louis, MO 63108. Revised 01/2012

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/21/2016

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.